Clinical trials: Flu Vaccine
Influenza
A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in Bangladesh
This is a single center, multi-site, double-blind, parallel group, placebo-controlled trial of the clinical efficacy of trivalent Serum Institute of India, Ltd.
- Trial name
- NCT01797029
- Testing
- SIIL Live Attenuated Influenza Vaccine
- Where
- 2 sites in Bangladesh
- Volunteers
- 1,761 people, healthy volunteers welcome
- Sponsor
- PATH
Human Influenza
Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents
Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection (trivalent, seasonal influenza vaccine, active ingredient content: 6 μg HA/strain/0.5 ml) for Children and Adolescents.
- Trial name
- NCT02387294
- Testing
- Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml), Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml)
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza A Subtype H5N1 Infection
Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1
This is a first-in-human study of safety and immunogenicity of an A/H5N1 inactivated whole cell vaccine when given in two injections in two doses (low and high) compared to a placebo in 76 healthy adult subjects in Vietnam.
- Trial name
- NCT02171819
- Testing
- IVACFLU-A/H5N1, 7.5 mcg, IVACFLU-A/H5N1, 15 mcg
- Where
- Vietnam
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Institute of Vaccines and Medical Biologicals, Vietnam
Influenza, Swine-origin A/H1N1 Influenza
A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly
The purpose of this study is to generate data on immunogenicity and safety of the monovalent H1N1 vaccine in support of the development and registration.
- Trial name
- NCT00954798
- Testing
- Swine A/H1N1 influenza vaccine (split virion, inactivated)
- Where
- 6 sites in France
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults
Influenza infection is related to significant morbidity and mortality in children. The trivalent inactive vaccine (TIV) has been documented to have poor immunogenicity in children and the live attenuated influenza vaccine (ATIV)…
- Trial name
- NCT02529904
- Testing
- MF59 - ATIV
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Healthy
Training Study to Characterize Biomarkers to Flu Vaccines
It is thought that vaccines trigger innate inflammatory responses to induce antigen-specific adaptive immunity (the desired effect), but excessive inflammation may lead to serious inflammatory complications or unwanted side…
- Trial name
- NCT01771367
- Testing
- Fluad, Agrippal
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Influenza
Phase 3 Trial of Serbian Seasonal Influenza Vaccine
A Phase 3, double-blind, randomized, placebo-controlled trial of a seasonal, trivalent, split, inactivated influenza vaccine produced by InstituteTorlak.
- Trial name
- Torlak-300 (NCT02935192)
- Testing
- Vaccine
- Where
- 6 sites in Serbia
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Institute of Virology, Vaccines and Sera, Torlak
Influenza
Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above
To evaluate the immunogenicity of administering one dose of influenza virus split vaccine (0.7mL/dose) to individuals aged 60 and above.
- Trial name
- NCT07327398
- Testing
- Influenza virus split vaccine (0.7mL/vial), Influenza virus split vaccine
- Where
- 2 sites in China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Healthy
A Study to Describe Pediatric Influenza Vaccine Coverage
The purpose of this study is to describe flu vaccine coverage in children under 18 years of age and to examine correlations between in-office flu vaccine coverage and the use of various tactics to increase vaccine coverage.
- Trial name
- NCT00639418
- Testing
- Influenza vaccination
- Where
- 187 sites in United States
- Volunteers
- 147,494 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza, Human, Infections
Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults
This Phase 1, randomized, observer-blind, dose-ranging clinical study is evaluating 6 different formulations of MF59-adjuvanted and non-adjuvanted H2N3 influenza vaccine.
- Conditions
- Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases
- Trial name
- NCT05875961
- Testing
- Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59
- Where
- 7 sites in United States, Philippines
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine
The purpose of this study is to evaluate the immunogenicity and safety of Northern hemisphere 2013-2014 seasonal trivalent inactivated influenza vaccine in 60 healthy infants aged 6-35 months old, 60 healthy adults aged 18-60…
- Trial name
- NCT02269852
- Testing
- trivalent seasonal influenza vaccine
- Where
- China
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults
1. To assess the safety, reactogenicity, tolerability, and adverse events (AEs) of the VAX102 vaccine in a two dose regimen (Day 0 and Day 28) at the 1.0 µg dose level delivered i.m., or the 2.0 µg dose level delivered s.c.
- Trial name
- NCT00921947
- Testing
- VAX102
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
Influenza
Adjuvanted Influenza Vaccine Evaluation in Kidney Transplant Recipients
Influenza is an important public health problem. Organ transplant patients are particularly susceptible to severe disease. Also, they shed higher quantities of virus for longer durations, leading to greater contagious potential…
- Trial name
- NCT01584908
- Where
- Canada
- Volunteers
- 68 people
- Sponsor
- University of Alberta
Influenza
A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of Age
This study will evaluate the safety and immunogenicity of different combinations of influenza vaccine in healthy young children.
- Trial name
- NCT00848887
- Testing
- Adjuvanted and un-adjuvanted influenza vaccines
- Where
- Belgium
- Volunteers
- 410 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
Pharma-Pen (Formerly Innoject) Auto-injectory TIV
The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained users to self-administer Influenza…
- Trial name
- NCT00335855
- Testing
- Auto-injector for IM/SC vaccine administration
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immunization; Infection, Transplantation Infection
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Lung allograft recipients have a higher burden of influenza disease and greater associated morbidity and mortality compared with healthy controls.
- Conditions
- Immunization; Infection, Transplantation Infection, Influenza
- Trial name
- NCT05215327
- Testing
- High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- Vanderbilt University Medical Center
Prophylaxis of Influenza
Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2012/2013 Season
Annual study to investigate influenza vaccine (flu vaccine) developed for the 2012/2013 season for the prevention of influenza infection. The immunizing effect is being investigated, as well as its tolerability and safety.
- Trial name
- NCT01633749
- Testing
- Trivalent influenza subunit vaccine Influvac
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals
Influenza
Clinical Trial of the Inactivated Influenza Vaccine (0.25ml Formulation for Pediatric Use)
The clinical trial was designed to evaluate the immunogenicity and safety against pediatric Inactivated influenza vaccine (Split Virion) (0.25ml formulation) of Hualan administered on infants age 6 months to 36 months.
- Trial name
- NCT01554826
- Testing
- Influenza Split Vaccine, Inactivated Influenza Vaccine
- Where
- China
- Volunteers
- 810 people, healthy volunteers welcome
- Sponsor
- Hualan Biological Engineering, Inc.
Influenza Immunization
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5413 compared to an…
- Trial name
- NCT05650554
- Testing
- Quadrivalent Influenza mRNA Vaccine MRT5413, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 682 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Behavior and Behavior Mechanisms
Nationwide Utilization of Danish Government Electronic Letter System for Increasing InFLUenza Vaccine Uptake Among Adults With Chronic Disease
In randomized clinical trials and observational studies, influenza vaccination has been shown to be effective in reducing influenza-related illness, hospitalizations, cardiovascular events, and mortality in select populations.
- Trial name
- NCT06030739
- Testing
- Behavioral Economic Principles
- Where
- Denmark
- Volunteers
- 299,881 people
- Sponsor
- Tor Biering-Sørensen